Agenus Inc.

Nasdaq AGEN · Lexington, MA

Works in Cardiovascular · Dermatology · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health

Agenus Inc. is a clinical trial sponsor based in Lexington, MA, listed as Nasdaq AGEN. It has 2 active clinical trials with 733 planned participants, across 11 therapeutic areas. Since 2021 it has completed 10 trials and stopped 7 early.

Trial track record · since 2021

2Active trials733 planned participants
10Completed5 with results posted
7Stopped early41% of finished trials

Financials · Nasdaq AGEN

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 2 active trials

StageTrialStatus

Questions about Agenus Inc

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-19.

Approve Suite is not affiliated with Agenus Inc..

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.